HALO News and Press, Halozyme Therapeutics Inc. From 11/05/21

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Halozyme Therapeutics, inc (NASDAQ: HALO) Q3 2021 Earnings Call Nov 2, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcrip...

Halozyme Therapeutics, Inc. (HALO) Q3 2021 Earnings Conference Call November 03, 2021, 04:30 PM ET Company Participants Al Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and CEO Elaine Sun - CFO Conference Call Participants Charles Duncan ...

A 145% increase in royalties in Q3 2021, primarily from sales of Darzalex (daratumumab), helped lead Halozyme Therapeutics (NASDAQ:HALO) to an earnings beat. Royalty revenue in the quarter was $58.6M, up from $23.9M in the prior-year period. Net product sales surged ~177% to ~25M. Operating e...

Halozyme Therapeutics (NASDAQ:HALO): Non-GAAP EPS of $0.55 beats by $0.07; GAAP EPS of $1.48 beats by $1.06. Revenue of $115.83M beats by $9.99M. Press Release Guidance Revenues of $430 million to $445 million, increased from prior guidance of $425 million to $445 million, representing year-o...

Halozyme Reports Third Quarter 2021 Results - Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 - - Third Quarter Revenue of $115.8 million with GAAP Diluted Earnings per Share of $1.48 and Non-GAAP Diluted Earn...

Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , Oct. 19, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on...

Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed. Small Pharma Analyst shares a lon...

Low risk biotech with steadily increasing revenue and earnings from ENHANZE drug delivery. Revenue and earnings are expected to peak at end of the decade with a long tail into the mid-2030s. Sizeable earnings provide ample cash for acquisitions or partnerships that will likely kee...

Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference PR Newswire SAN DIEGO , Sept. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun , senior vice president and chief financial ...